IRIDEX (NASDAQ:IRIX) Coverage Initiated by Analysts at StockNews.com

by · The Markets Daily

StockNews.com initiated coverage on shares of IRIDEX (NASDAQ:IRIX – Free Report) in a report released on Monday morning. The brokerage issued a hold rating on the medical equipment provider’s stock.

IRIDEX Price Performance

IRIDEX stock opened at $1.80 on Monday. IRIDEX has a 1 year low of $1.27 and a 1 year high of $3.65. The company has a current ratio of 1.54, a quick ratio of 0.85 and a debt-to-equity ratio of 0.55. The firm has a market capitalization of $29.95 million, a P/E ratio of -2.69 and a beta of 0.80. The business has a 50-day moving average of $1.64 and a 200-day moving average of $1.96.

IRIDEX (NASDAQ:IRIX – Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The medical equipment provider reported ($0.12) EPS for the quarter. The business had revenue of $11.58 million for the quarter. IRIDEX had a negative return on equity of 192.95% and a negative net margin of 22.79%. During the same quarter in the prior year, the company posted ($0.11) earnings per share.

IRIDEX Company Profile

(Get Free Report)

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.

Recommended Stories